Risk stratification model based on VEGF and International Prognostic Index accurately identifies low-risk diffuse large B-cell lymphoma patients in the rituximab era

Autor: Ziyuan Shen, Shanlin Nie, Yuanyuan Qin, Dongyun Tu, Wei Sang, Xuguang Song, Zhenyu Li, Yuhan Ma, Yingliang Jin, Kailin Xu, Cai Sun, Linyan Xu, Zhenzhen Bian, Hang Zhou, Dongmei Yan
Rok vydání: 2021
Předmět:
Oncology
Adult
Male
Vascular Endothelial Growth Factor A
medicine.medical_specialty
Angiogenesis
medicine.medical_treatment
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
International Prognostic Index
Antineoplastic Agents
Immunological
immune system diseases
hemic and lymphatic diseases
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Biomarkers
Tumor
Humans
Molecular Targeted Therapy
Aged
Aged
80 and over
Hematology
business.industry
Retrospective cohort study
Immunotherapy
Middle Aged
medicine.disease
Prognosis
Immunohistochemistry
Survival Analysis
Vascular endothelial growth factor
Treatment Outcome
chemistry
030220 oncology & carcinogenesis
Rituximab
Female
Lymphoma
Large B-Cell
Diffuse
business
Diffuse large B-cell lymphoma
030215 immunology
medicine.drug
Zdroj: International journal of hematology. 114(2)
ISSN: 1865-3774
Popis: Vascular endothelial growth factor affects the invasiveness of solid tumors by regulating angiogenesis. However, it is not clear whether VEGF could be used to predict the prognosis of DLBCL in the era of rituximab-based immunotherapy. We conducted a retrospective study to explore response to therapy and the prognostic value of VEGF on DLBCL in the rituximab era. The subjects were 65 patients with a histological diagnosis of DLBCL from the Affiliated Hospital of Xuzhou Medical University. Kaplan-Meier analysis was performed to estimate the cumulative survival rate of patients with different VEGF and IPI levels, and comparisons between groups were made using the log-rank test. DLBCL patients with elevated VEGF were more likely to have extranodal involvement, advanced stage, Myc/Bcl-2 double expression, and a higher Ki-67 score. Elevated VEGF was associated with poor therapeutic response and survival. When patients were divided into low, low-intermediate, high-intermediate and high-risk groups using the V-IPI model based on VEGF and IPI, PFS rates were 94.4, 74.1, 40.6 and 14.8%, respectively. This model better identified low-risk patients than IPI (85.9, 88.9, 37 and 7.8%). Our results demonstrate that VEGF predicts therapeutic response in DLBCL and the V-IPI model accurately predicts PFS of low-risk DLBCL in the rituximab era.
Databáze: OpenAIRE
Externí odkaz: